The Washington Post
Free genes from patent restrictions
Jolie revealed last week that she chose to undergo a double mastectomy after testing positive for the BRCA1 mutation.
Sun May 19, 2013
IP regime benefits US monopolies
THE US Supreme Court recently began deliberations in a case that highlights a deeply problematic issue concerning intellectual property rights.
Worcester Telegram & Gazette
Gene test may help guide prostate cancer treatment
A new genetic test to gauge the aggressiveness of prostate cancer may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it.
Fri May 17, 2013
Angelina Jolie's Cancer Gene, BRCA1, in Focus at Supreme Court
Earlier this week, Angelina Jolie wrote a heartfelt op-ed in The New York Times about her decision to undergo a preventive double mastectomy.
Thu May 16, 2013
EXPOSED: Angelina Jolie part of a clever corporate scheme to protect...
EXPOSED: Angelina Jolie part of a clever corporate scheme to protect billions in BRCA gene patents, influence Supreme Court decision Angelina Jolie's announcement of undergoing a double mastectomy even though she had no breast cancer is not the innocent, spontaneous, "heroic choice" that has been portrayed in the mainstream media.
Lawyers Weekly USA
Will Jolie's announcement affect SCOTUS gene ruling? Probably not
Earlier this week the actress revealed that she underwent a preventative double mastectomy after she tested positive for a gene that indicates an increased risk for breast and ovarian cancer.
Wed May 15, 2013
The Myriad Case and 'Gene' Patents: Much Ado about Nothing?
The biggest concern of the biotechnology industry caused by the impending Supreme Court decision in the AMP v. Myriad Genetics case is the threat to existing patents having claims to isolated human DNA that a negative decision from the Court could raise.
Tue May 14, 2013
KRDO-TV Colorado Springs
Jolie's mastectomy highlights genetic testing company
Angelina Jolie's decision to undergo a preventative double mastectomy has put the spotlight on Myriad Genetics, the only company in the world that conducts genetic tests for breast cancer.
Can you really patent someone's genes?
On April 15, in the case of The Association for Molecular Pathology vs. Myriad Genetics, Inc.
Jolie's double mastectomy highlights Supreme Court 'cancer gene' patent battle
Angelina Jolie's double mastectomy revelation had the unintended side-effect of boosting the share price for the biotech firm that owns the patent to her "breast cancer gene," highlighting an ongoing US Supreme Court battle over the right to patent life.
NBC Bay Area
Jolie Brings Attention to Genetic Testing
The actress revealed in a New York Times op-ed that she underwent the surgery to prevent cancer.
Angelina Jolie's Cancer Testing and Corporate Control of Human Genes
Actress Angelina Jolie's announcement on Tuesday that she underwent a double mastectomy following genetic testing underscores the broad implications of an upcoming U.S. Supreme Court decision on whether corporations can own human genes.
The Washington Post
Angelina Jolie Had Mastectomy to Reduce Breast Cancer Risk
Angelina Jolie, named the highest- paid actress in Hollywood by Forbes in 2011, said she had a double mastectomy after learning she has a gene mutation linked to breast cancer, the disease that killed her mother at age 56.
Mon May 13, 2013
Sony Options Active As Shares Hit Fresh 52-Week High
SNE - Sony Corp - Big prints in Sony Corp. call and put options this morning pushed the consumer electronics maker onto our 'hot by options volume' market scanner in the early going on Monday, with overall volume up above 21,000 contracts versus the stock's average daily volume of roughly 8,000 contracts.
Sun May 12, 2013
Intellectual Property Rights Gone Wild
The Supreme Court recently began deliberations in a case that highlights a deeply problematic issue concerning intellectual property rights: Can human genes - your genes - be patented? Put another way, should someone essentially be permitted to own the right, say, to test whether you have a set of genes that imply a higher than 50 percent ... (more)
Sat May 11, 2013
Myriad Genetics Upgraded by Mizuho to "Buy"
The firm currently has a $34.00 target price on the stock, up from their previous target price of $27.00. Shares of Myriad Genetics traded up 8.60% during mid-day trading on Wednesday, hitting $33.10. Myriad Genetics has a 52 week low of $22.02 and a 52 week high of $31.80. The stock's 50-day moving average is currently $25.6. The company has a ... (more)
Fri May 10, 2013
Myriad Genetics's "Neutral" Rating Reaffirmed at Zacks
's stock had its "neutral" rating reiterated by Zacks in a research note issued to investors on Friday, StockRatingsNetwork reports.
Myriad Fights to Patent the Human Gene [Podcast]
Myriad Genetics has isolated a human DNA sequence used for tests to detect whether women are at a higher risk for breast or ovarian cancer.
Thu May 09, 2013
Myriad Genetics Now Covered by Analysts at Stephens
Shares of Myriad Genetics opened at 30.63 on Thursday. Myriad Genetics has a 52 week low of $22.02 and a 52 week high of $31.80. The stock's 50-day moving average is currently $25.6. The company has a market cap of $2.468 billion and a P/E ratio of 20.99. Myriad Genetics last issued its quarterly earnings data on Tuesday, May 7th.
Wed May 08, 2013
On The Fly: Pre-market Movers
Check below for free stories on FIO;WFM;EA;DAL;BBRY;AOL;MYGN;VCLK;CTSH;AXLL;Z;SYMC;SODA the last two weeks.